Current Progress in Pharmacogenetics of Second-Line Antidiabetic Medications: Towards Precision Medicine for Type 2 Diabetes

被引:21
|
作者
Heo, Chan Uk [1 ]
Choi, Chang-Ik [1 ]
机构
[1] Dongguk Univ Seoul, Coll Pharm, Goyang 10326, South Korea
基金
新加坡国家研究基金会;
关键词
pharmacogenetics; precision medicine; personalized medicine; type; 2; diabetes; second-line antidiabetic medications; DPP-4; inhibitors; GLP-1 receptor agonists; SGLT2; GLUCAGON-LIKE PEPTIDE-1; INADEQUATE GLYCEMIC CONTROL; GLUCOSE COTRANSPORTER 2; DIPEPTIDYL PEPTIDASE-4 INHIBITORS; CANNABINOID RECEPTOR GENE; GENOME-WIDE ASSOCIATION; EXENATIDE SYNTHETIC EXENDIN-4; SELECTIVE SGLT2 INHIBITOR; FAMILIAL RENAL GLUCOSURIA; FATTY LIVER-DISEASE;
D O I
10.3390/jcm8030393
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Precision medicine is a scientific and medical practice for personalized therapy based on patients' individual genetic, environmental, and lifestyle characteristics. Pharmacogenetics and pharmacogenomics are also rapidly developing and expanding as a key element of precision medicine, in which the association between individual genetic variabilities and drug disposition and therapeutic responses are investigated. Type 2 diabetes (T2D) is a chronic metabolic disorder characterized by hyperglycemia mainly associated with insulin resistance, with the risk of clinically important cardiovascular, neurological, and renal complications. The latest consensus report from the American Diabetes Association and European Association for the Study of Diabetes (ADA-EASD) on the management of T2D recommends preferential use of glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and some dipeptidyl peptidase-4 (DPP-4) inhibitors after initial metformin monotherapy for diabetic patients with established atherosclerotic cardiovascular or chronic kidney disease, and with risk of hypoglycemia or body weight-related problems. In this review article, we summarized current progress on pharmacogenetics of newer second-line antidiabetic medications in clinical practices and discussed their therapeutic implications for precision medicine in T2D management. Several biomarkers associated with drug responses have been identified from extensive clinical pharmacogenetic studies, and functional variations in these genes have been shown to significantly affect drug-related glycemic control, adverse reactions, and risk of diabetic complications. More comprehensive pharmacogenetic research in various clinical settings will clarify the therapeutic implications of these genes, which may be useful tools for precision medicine in the treatment and prevention of T2D and its complications.
引用
收藏
页数:28
相关论文
共 50 条
  • [1] Fournier's gangrene in patients with type 2 diabetes using second-line antidiabetic medications
    Petruski-Ivleva, Natalia
    Schneeweiss, Sebastian
    Eapen, Sara
    Rajan, Aditya
    Jan, Saira
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (02): : 267 - 271
  • [2] Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes
    O'Brien, Matthew J.
    Karam, Susan L.
    Wallia, Amisha
    Kang, Raymond H.
    Cooper, Andrew J.
    Lancki, Nicola
    Moran, Margaret R.
    Liss, David T.
    Prospect, Theodore A.
    Ackermann, Ronald T.
    [J]. JAMA NETWORK OPEN, 2018, 1 (08)
  • [3] Type 2 diabetes: second-line antidiabetic therapy in early pregnancy
    Clauss, Maria
    [J]. ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE, 2024, 228 (02): : 119 - 119
  • [4] Patient Preferences Informing Choice of Second-Line Type 2 Diabetes Medications
    Golembiewski, Elizabeth
    Garcia, Andrea E.
    Polley, Eric
    Umpierrez, Guillermo
    Galindo, Rodolfo J.
    Brito, Juan
    Montori, Victor M.
    Mickelson, Mindy
    Mccoy, Rozalina G.
    [J]. DIABETES, 2023, 72
  • [5] PATIENT PREFERENCES FOR SECOND-LINE MEDICATIONS TO MANAGE TYPE 2 DIABETES MELLITUS
    Ozdemir, Semra
    Baid, Drishti
    Verghese, Naina
    Lam, Amanda Yun Rui
    Lee, Phong Ching
    Ying, Lim Adoree Yi
    Zhu, Ling
    Finkelstein, Eric A.
    Goh, Su-Yen
    [J]. MEDICAL DECISION MAKING, 2020, 40 (01) : E286 - E287
  • [6] Choice of second-line antidiabetic treatment in Type 2 diabetes: influence of patient characteristics
    Zghebi, S. S.
    Steinke, D. T.
    Rutter, M. K.
    Ashcroft, D. M.
    [J]. DIABETIC MEDICINE, 2015, 32 : 205 - 205
  • [7] Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
    Florez, Jose C.
    [J]. DIABETOLOGIA, 2017, 60 (05) : 800 - 807
  • [8] Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
    Jose C. Florez
    [J]. Diabetologia, 2017, 60 : 800 - 807
  • [9] Second-line Therapy for Type 2 Diabetes
    Krome, Susanne
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2024, 149 (19) : 1127 - 1128
  • [10] Initiating second-line antidiabetic medication among older adults with type 2 diabetes on Metformin
    Kristen DeCarlo
    Amisha Wallia
    Raymond H. Kang
    Andrew Cooper
    Manisha Cherupally
    Sterling A. Harris
    Cassandra Aikman
    David T. Liss
    Ronald T. Ackermann
    Matthew J. O’Brien
    [J]. BMC Geriatrics, 22